Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinomaCarol Box, Marta Mendiola, Sharon Gowan, et al.Clinical and Translational Radiation Oncology|February 20, 2020
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trialJulia Murray, Sarah Gulliford, Clare Griffin, et al.Expert Opinion on Biological Therapy|February 19, 2020
Combination therapy with oncolytic viruses and immune checkpoint inhibitorsMatthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, et al.European Urology Oncology|September 7, 2021
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)John N Staffurth, Joanne S Haviland, Anna Wilkins, et al.The Lancet. Oncology|November 3, 2015
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trialAnna Wilkins, Helen Mossop, Isabel Syndikus, et al.Clinical and Translational Radiation Oncology|October 14, 2022
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentationJulia Murray, Clare Cruickshank, Thomas Bird, et al.Journal for Immunotherapy of Cancer|March 8, 2021
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancerAnna Wilkins, Elisa Fontana, Gift Nyamundanda, et al.International Journal of Radiation Oncology, Biology, Physics|May 22, 2025
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation TherapySian Cooper, Rosalyne L Westley, Katie Biscombe, et al.Nature Cancer|July 12, 2024
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancerJavier Fernandez-Mateos, George D Cresswell, Nicholas Trahearn, et al.The Journal of Clinical Investigation|November 7, 2023
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammationMagnus T Dillon, Jeane Guevara, Kabir Mohammed, et al.Pageof 5